Previous 10 | Next 10 |
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against ca...
2024-01-29 09:18:44 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax Read the full article on Seeking Alpha...
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has ap...
Strengthening GeoVax’s Team Advancing Gedeptin® Clinical Program ATLANTA, GA - ( NewMediaWire ) - January 08, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, t...
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA - ( NewMediaWire ) - January 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology co...
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology compan...
2024-01-02 16:23:19 ET More on GeoVax GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on GeoVax Historical earnings data for GeoVax Financial information for GeoVax For further details see: GeoVax Labs...
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will present at the Bi...
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has amended a previously executed Patent and Biological M...
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...
News, Short Squeeze, Breakout and More Instantly...
GeoVax Labs Inc. Company Name:
GOVX Stock Symbol:
OTCMKTS Market:
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs...
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA - ( NewMediaWire ) - April 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced...
ATLANTA, GA - ( NewMediaWire ) - March 28, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-...